#rGBM
Palette of the Day:

8-Bit RGBM by A.J. Otero

#lospecdailies #8bitrgbm #palette

Download: https://lospec.com/palette-list/8-bit-rgbm
October 15, 2025 at 7:00 AM
🤘🏾🙂‍↕️🤘🏾
music.youtube.com/watch?v=Rgbm...
Cherry
YouTube video by Naomi Scott - Topic
music.youtube.com
April 21, 2026 at 9:30 PM
September 11, 2024 at 10:56 PM
After 6 years of being involved in early phase clinical trials, I was honored to present data from our Phase 0/2 study exploring CDK4/6i +ERKi in rGBM patients. Grateful to the collaborative team, patients and their families #SNO2024
November 23, 2024 at 8:12 PM
se o papa fosse hermafrodita
se o papa fosse hermafrodita
o aborto seria legal ♫⋆。♪ ₊˚♬ ゚.
February 12, 2025 at 4:14 PM
Very excited to have this collaborative work on evaluating PK/PD and single-cell responses for Ribociclib+Everolimus in #rGBM published. It was such a great experience working with @kevin-johnson.bsky.social and @roelverhaak.bsky.social. @ivycenter.bsky.social @anchitien.bsky.social
November 8, 2025 at 6:04 PM
Oooh, I see, one reason to use octahedral environment maps is that it simplifies doing something like RGBM encoding where you might implement your own bilinear filtering in the shader

Also enables packing them into texture arrays (which have much wider hw support than cube arrays)
Oh. Huh. Today I learned about octahedral environment maps :O
December 7, 2025 at 12:12 AM
alright it's bed time. I misread a post about RGBM encoding and was just ready to accept that Ranked Competitive Breast Growth had octahedral environment maps

I'm a couple months behind, Katherine could've done anything by now
December 7, 2025 at 12:26 AM
A isenção do Imposto de Renda atinge diretamente os brasileiros que estarão no centro da disputa em 2026. O Planalto sabe disso. O Congresso também.

Assista à análise de Pedro Doria no Ponto de Partida: www.youtube.com/watch?v=rGBM...

#meio #pontodepartida #impostoderenda #eleicoes2026 #politica
October 1, 2025 at 9:48 PM
Tak pro velky uspech - takhle se to da cele rozdelat a slozit, kdybyste nahodou potrebovali. www.youtube.com/watch?v=Rgbm...
March 29, 2026 at 7:39 PM
Unraveling the functional complexity of the tumor microenvironment via #spatialbiology. The 2 images show rGBM tissue with cell signaling cell plot (left) & cell-type mIHC (right). Neoplastic, vascular & immune cells show distinct signals which correlate with cell clustering & proximity to ECM
December 18, 2024 at 9:31 AM
URJANET 🚨 com 17 votos, Janet Jackson foi eleita melhor cantora da história em votação realizada pelo blogspot especializado "♡Janet Jackson Lovers♡"
September 2, 2024 at 4:34 AM
GÊNIO: você tem 3 desejos

Janet: faça que todas as palavras tenham 5
letras

Gênio: okayy

Janet: façaa todas aasss plvrs terem NET nnooo
final

Gênet: oknet

Janet: fanet tonet asnet pinet tenet JA nonet
conet

Janet: Janet

Janet: Janet
September 2, 2024 at 2:32 PM
kre.pe/j3cW
kre.pe/rGBM
크레페에 커미션을 개장했습니다. 한 번씩 둘러봐 주시면 감사하겠습니다!
얼음조각님의 털뭉치 크리쳐 타입 | CREPE
얼음조각님의 털뭉치 크리쳐 타입, CREPE에서 신청할 수 있어요.
kre.pe
April 21, 2025 at 2:45 PM
One of two dippers seen in the Seven Arches (Balmossie) Viaduct area of the Dighty Burn in Monifieth/Broughty Ferry, Dundee on a Friday walk on a bright chilly afternoon. A 5yo male RGBM/CL97968. 📷📸🎞️🪶 #birds #ukwildlife
March 29, 2025 at 12:37 AM
www.youtube.com/watch?v=rGBM... You wanted to know about this, so here you go.
NIOD Annual Lecture 2026: Omer Bartov
YouTube video by NIODFilm
www.youtube.com
June 4, 2026 at 2:50 PM
Sept 29, 2025:

DCVax-L increased the 4-year survival rate to 15.7% in the nGBM cohort v 9.9% in controls. In the rGBM cohort the #DCVax-L group showed a significantly higher mOS (13.2 m vs. 7.8 m).
💪
#FreezeYourTumor
#GetDCVax

$nwbo #glioblastoma #gbm

cancerbiomed.org/content/cbm/...
October 2, 2025 at 4:54 PM
The mOS for 64 rGBM patients who underwent #DCVax-L and control patients were 13.2 mos and 7.8 mos, respectively. The mOS for 232 nGBM patients who underwent DCVax-L and control patients were 19.3 mos and 16.5 mos, respectively.
💪
$nwbo #glioblastoma #gbm
pmc.ncbi.nlm.nih.gov/articles/PMC...
June 10, 2025 at 3:24 PM
Can recurrent #Glioblastoma be overcome by targeting several #Oncogenic nodes at once? LiPBAE-delivered miR-590-3p nanomiRs inhibit the TGFBR2–SMAD network, suppress orthotopic rGBM growth, and prolong survival in mice. @jhu.edu

#STTT #OpenAccess: doi.org/10.1038/s413...
September 3, 2026 at 2:45 AM
The skybox is a 2K x 1K webp image and comes in at just 250KB.

It is a lossy encoded medium dynamic range image using our own "rgbp" format, which is similar to rgbm, but better suited to the way older browsers handle image alpha.

The scene: t.co/8hpbxikar9

The skybox: t.co/13SNzhG4Qf
March 1, 2025 at 8:30 PM
Full results of this first-in-class phase 1 clinical trial for recurrent glioblastoma now available online first ahead of print in Clinical Cancer Research -- aacrjournals.org/clincancerre...
A genomically-tailored multi-agent precision medicine clinical trial for adults with recurrent glioblastoma
Abstract. Purpose: Existing salvage therapies for recurrent glioblastoma (rGBM) have limited efficacy, with median survival of approximately 9 months. Given the complex molecular heterogeneity of GBM,...
aacrjournals.org
February 8, 2026 at 12:19 AM
Three of eight dippers seen (likely 3 pairs) in the Seven Arches (Balmossie) Viaduct area of the Dighty Burn in Monifieth/Broughty Ferry, Dundee on my Saturday walk on a dingy grey day. 1st/2nd pic: 5yo male RGBM/CL97968, 3rd pic: metal-ringed, 4th pic: colour-ringed RGLM. 📷📸🎞️🪶 #birds #ukwildlife
March 23, 2025 at 1:36 AM
Intracranial delivery of B7-H3-targeting CAR-T cells for recurrent glioblastoma: a phase 1 trial
Recurrent glioblastoma (rGBM) is a leading brain malignancy with few therapeutic options. Here we present the complete results of a phase 1 trial investigating the safety and efficacy of autologous B7-H3-targeting chimeric antigen receptor T (CAR-T) cell (TX103) therapy for the treatment of rGBM. In this open-label, 3 + 3 dose-escalation trial, patients aged 18–75 years with B7-H3-positive (≥30%) rGBM received intracranial infusion of TX103 at three dose levels (DLs—2 × 107, 6 × 107 and 1.5 × 108 cells per infusion). Primary endpoints were safety, maximum tolerated dose (MTD), and recommended phase 2 dose (RP2D). Secondary endpoints included survival, pharmacokinetics and immunological response. Fifteen patients received a total of 72 intracranial infusions and 13 underwent repeated infusions. TX103 therapy was well tolerated, with no dose-limiting toxicities or MTD identified. Treatment-related adverse events (TRAEs) included low-grade cytokine release syndrome (86.7%), sinus tachycardia (53.3%), vomiting (53.3%), hypertension (53.3%) and elevated intracranial pressure (46.7%). Three grade 3 TRAEs considered serious adverse events occurred (elevated intracranial pressure, epilepsy and depressed consciousness), two at DL3. The 12-month overall survival (OS) rate was 66.7% and median OS was 19.1 months (95% confidence interval = 8.93, not reached) from first infusion. Disease control (stable disease or...
www.nature.com
August 7, 2026 at 5:07 AM